VAXCYTE INC
Vaxcyte Inc (PCVX) is a clinical-stage biotechnology company focused on developing next-generation vaccines. The company’s lead programmes include a pneumococcal conjugate vaccine candidate designed to broaden serotype coverage and other vaccine candidates targeting infectious diseases such as Lyme. With a market capitalisation around $5.50B, Vaxcyte’s valuation reflects investor expectations of successful clinical progress and eventual commercialisation. As a clinical-stage firm it currently has limited product revenue and depends on trial outcomes, partnerships and funding to advance its pipeline. Key investor considerations are trial results, regulatory decisions, competitive dynamics in the vaccine market and manufacturing scale-up. Risks are material: clinical setbacks, regulatory delays, manufacturing challenges and dilution from financing can all affect the share price. This summary is educational only — not investment advice — and suitable for investors who understand biotech risk and a long time horizon.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Vaxcyte's stock with a target price of $100.22, indicating strong growth potential.
Financial Health
Vaxcyte is showing strong cash flow and solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PCVX
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Late-stage pneumococcal play
Vaxcyte’s pneumococcal candidate aims to expand serotype coverage, which could address unmet need — though success depends on clinical and regulatory outcomes.
Platform-driven vaccine pipeline
A proprietary platform supports multiple candidates, offering leverage if one succeeds; early-stage programmes add upside but also add development risk.
Commercial and competitive dynamics
The global vaccine market offers scale if approved, but competition from established vaccine makers and manufacturing challenges can affect commercial prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
